Holen Sie sich die Stockscreener-App
208.45
1.27%
2.61
Handel nachbörslich:
207.05
-1.40
-0.67%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$205.84
Offen:
$206.39
24-Stunden-Volumen:
1.47M
Relative Volume:
1.01
Marktkapitalisierung:
$30.24B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
20.09
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
-0.56%
1M Leistung:
+5.84%
6M Leistung:
-17.44%
1J Leistung:
-18.57%
1-Tages-Spanne:
$205.00
$209.33
1-Wochen-Bereich:
$205.00
$222.43
52-Wochen-Spanne:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
208.45 | 29.86B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
411.55 | 147.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
150.85 | 41.49B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.85 | 34.08B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.14 | 32.46B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Analyst Backs Portfolio Reset - Benzinga
ResMed's Q4 2026 Earnings: What to Expect - Barchart.com
What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares? - Kalkine
Form 4 ResMed Inc For: 9 July By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing - marketscreener.com
ResMed chairman & CEO Michael Farrell sells $1.09m in company stock - Investing.com Canada
ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan - Stock Titan
ResMed Inc. highlights sleep and respiratory focus as investors track Nasdaq-listed shares - Ad-hoc-news.de
ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says - marketscreener.com
ResMed to sell MatrixCare business to Frazier Healthcare Partners - MSN
ResMed's billion-dollar blowup - intelligentinvestor.com.au
ResMed Willing to Cut Underperforming Assets -- Market Talk - Moomoo
ResMed Inc. stock falls Wednesday, underperforms market - MSN
Is ResMed Inc (RMD) a Bargain After 6.3% Drop? GF Value Says Und - GuruFocus
Resmed Agrees to Sell its Software Business to a Private Equity Firm - Medical Product Outsourcing
Why ResMed Is Dropping 5.7%: RBC Capital Maintains Outperform - AlphaStreet
ResMed (NYSE:RMD): Why The Market Is Watching? - Kalkine Media
Resmed to sell MatrixCare for $490M to private equity firm - RamaOnHealthcare
ResMed Inc. focuses on sleep and respiratory care. Long-term demand supports the business model. - AD HOC NEWS
ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says - marketscreener.com
RBC Capital Maintains ResMed(RMD.US) With Buy Rating, Cuts Target Price to $276 - Moomoo
ResMed stock held at Hold by Needham as MatrixCare sale announced - Investing.com
Frazier Healthcare Partners Acquires MatrixCare - Hospice News
Resmed sharpens sleep care focus with $490m software business sale - Yahoo Finance
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $225 to $320 - Moomoo
ResMed Sells MatrixCare Software Business For $490m In Portfolio Overhaul - insights.citeline.com
Wells Fargo Adjusts Price Target on ResMed to $225 From $227 - marketscreener.com
RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating - marketscreener.com
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion - ChartMill
ResMed Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Health Care Roundup: Market Talk - Moomoo
Australian Shares Fall; ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $490 Million - Moomoo
ResMed to Divest MatrixCare Business for $490 Million to Focus on Sleep and Connected Care Markets - Kalkine
ResMed Bull Sees Divestment Sharpening Strategic Focus -- Market Talk - Moomoo
ResMed's MatrixCare Sale May Hint at AI Disruption Risk -- Market Talk - Moomoo
ResMed sharpens core focus with US$490 million MatrixCare sale - Proactive financial news
Frazier Healthcare Partners to acquire MatrixCare from ResMed - MSN
Australia's ResMed sells MatrixCare business for $490M - grafa.com
ResmedReiterates Q4 FY2026 Outlook for Net - Moomoo
What Does ResMed's (ASX:RMD) MatrixCare Sale Mean for Its Future Growth Strategy? - Kalkine Media
Resmed (RMD) Sells MatrixCare to Frazier Healthcare Partners - GuruFocus
ResMed’s $490m MatrixCare sale: What it means - The Motley Fool Australia
ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $490 Million - Moomoo
ResMed to sell software business MatrixCare for $490 million - Reuters
RMD: Frazier Healthcare Partners to Acquire MatrixCare from Resmed - GuruFocus
ResMed Sells MatrixCare to Frazier Healthcare to Focus on Sleep and Connected Home Health Markets 1 - Minichart
Resmed Sees 3Q Closing for MatrixCare Divestiture -- Company Talk - Moomoo
Frazier Healthcare Partners to Acquire MatrixCare from ResMed (R - GuruFocus
Frazier Healthcare to acquire MatrixCare from ResMed By Investing.com - Investing.com South Africa
Frazier Healthcare to acquire MatrixCare from ResMed - Investing.com
Resmed to sell MatrixCare in private equity deal - Stock Titan
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):